Medical debt remains one of the most common and devastating financial challenges facing patients in the United States. For individuals navigating serious illnesses such as cancer, the financial strain of treatment can follow them long after they leave the hospital.
A new analysis from the National Consumers League (NCL) sheds light on an important dimension of this issue: how hospitals participating in the federal 340B drug pricing program approach medical debt collection. The issue brief examines hospital billing and collection policies across more than 2,500 hospitals nationwide, comparing those that participate in the 340B program with those that do not.
The findings raise important questions about how hospital financial policies intersect with the experience of patients already navigating complex medical care.
The 340B Drug Pricing Program allows eligible hospitals and clinics serving large numbers of underserved patients to purchase outpatient medications at discounted prices. The intent of the program is to help healthcare providers expand services and improve care for vulnerable populations.
At the same time, the NCL analysis finds that hospitals participating in the program are more likely to maintain policies that allow aggressive medical debt collection actions.
Among the hospitals studied:
The report also finds that these policies remain common even in hospitals treating large numbers of cancer patients, where continuity of care and financial stability are especially important for patients undergoing long and complex treatment.
The analysis highlights the difficult balance between hospital finances and patient affordability, particularly when patients facing serious illness may already be vulnerable to financial hardship.
For many Americans, medical debt arises not from discretionary healthcare choices but from unexpected or unavoidable illness. Cancer treatment, emergency care, chronic disease management, and complex procedures can all lead to significant out-of-pocket expenses.
Financial strain can also affect health outcomes. When patients fear debt, damaged credit, or legal consequences from unpaid medical bills, they may delay or skip follow-up care, which can compromise recovery and long-term health.
The NCL report points to a broader policy question: whether the financial benefits hospitals receive through the 340B program are consistently translating into reduced financial burdens for the patients the program was designed to serve.
At Patients Rising, we believe patient voices are essential to understanding healthcare policy.
While policy reports and national data provide important insights, the real impact of medical debt is best understood through the experiences of patients and families navigating the healthcare system.
That is why Patients Rising has begun a multi-state review of medical bankruptcy filings as part of our Medical Bankruptcy in America series, examining how 340B hospital billing and debt collection practices affect patients in real life.
Through this effort, we are examining:
This work is intended to complement existing research and help illuminate how financial pressures intersect with healthcare access.
Healthcare policy discussions often focus on system-level structures and financial models. But behind every statistic is a patient navigating treatment, recovery, and the financial realities of medical care.
In the coming months, Patients Rising will share stories and analysis from this work to help bring greater visibility to the patient experience with medical debt.
Our goal is simple: to ensure that conversations about healthcare affordability include the voices and experiences of the people most directly affected.